prfx stock — PRFX (PainReform Ltd.) Overview

PRFX (PainReform Ltd. / PRF Technologies) — stock

Lead

PRFX stock is the Nasdaq ticker for PainReform Ltd., an Israel‑based pharmaceutical and health‑technology company that trades ordinary shares on the Nasdaq exchange. This article focuses on PRFX stock as an equity security (not a cryptocurrency) and provides a comprehensive company, clinical and market overview useful to researchers and investors.

As of 2026-01-27, according to Nasdaq and MarketWatch, PRFX stock remains a small‑cap publicly traded equity; readers should consult primary filings and market pages for the most current quotes and metrics.

Company overview

PRFX stock represents ownership in PainReform Ltd., a company focused on reformulation of established therapeutics and development of related platforms targeting pain management and ocular therapies. PainReform is headquartered in Israel and was founded with the stated mission of enhancing safety, efficacy or delivery of known drug molecules through reformulation or novel delivery systems. The company’s early identity and product focus have been associated primarily with analgesic and ophthalmic development programs.

Across public disclosures, the company describes two broad operational pillars that define its activities: (1) R&D in reformulated therapeutics (referred below as product candidates such as PRF‑110 and ocular platforms) and (2) pursuit of strategic diversification through technology, energy or platform acquisitions to broaden potential revenue sources and IP. PRFX stock captures market exposure to both these development‑stage therapeutic programs and the company’s strategic corporate moves.

As of 2026-01-27, according to TradingView and Nasdaq summaries, PRFX stock is characterized by low average daily trading volume relative to mid‑ and large‑cap biopharma names, a feature typical of micro‑cap clinical‑stage companies.

Corporate history

• Founding and early years: PainReform Ltd. was established to focus on reformulation and repositioning of existing drug molecules to improve patient outcomes and commercial viability. The company’s early public identity emphasized pain and ophthalmic therapy reformulation programs.

• Public listing / IPO: PRFX stock began trading on the Nasdaq exchange following the company’s IPO or direct listing event (see the company’s SEC filings and Nasdaq summary for exact listing date and registration materials). As of 2026-01-27, Nasdaq and MarketWatch list the company under the ticker PRFX.

• Name changes and rebranding: In public communications and market pages, the company has been referenced under the name PainReform Ltd. and in some sources under a branding reference to PRF Technologies. These references reflect either shorthand branding or formal name changes disclosed in corporate filings or press releases. As of 2026-01-27, company profiles on MarketWatch and Nasdaq reference both PainReform Ltd. and PRF Technologies in different contexts.

• Strategic shifts: Over time, the company announced strategic diversification beyond its core reformulation R&D. Public announcements have referenced pilot activities or acquisitions in adjacent technology areas, including energy‑related pilots and synthetic biology/biotech platform investments. As of 2026-01-27, these diversification efforts are reflected in press releases and market summaries and are cited by financial pages tracking PRFX stock.

Business operations and products

PRFX stock is tied to PainReform’s portfolio of product candidates and platform initiatives. The company’s public disclosures and market pages highlight several operational focal points:

• Reformulated therapeutics: The core R&D strategy centers on reformulating established compounds to create product candidates that may offer improved delivery, reduced side effects or differentiated IP. Example program names cited in public materials include PRF‑110 and ocular platform projects. PRF‑110 is often described as a reformulation candidate aimed at specific pain indications; public pages for PRFX stock list PRF‑110 among the company’s lead programs.

• Ocular platforms: PainReform’s ocular program work targets ophthalmic delivery and reformulation for established molecules or improved topical/systemic options. These programs typically pursue preclinical and early clinical validation prior to regulatory interactions.

• Diversification projects: Public announcements associated with PRFX stock reference acquisitions, pilots or majority investments into entities such as LayerBio (a biotech/biomaterial interest) and DeepSolar (an energy‑adjacent pilot), intended to diversify revenue and technology exposure. These transactions are described in company press releases as strategic moves to access adjacent markets or platform technologies.

• Business model: The company’s stated model is development‑stage—advance product candidates through preclinical and clinical stages, partner or license programs where feasible, and pursue opportunistic acquisitions to build long‑term value. PRFX stock therefore reflects exposure to R&D progress and corporate execution on transaction pipeline activity.

Markets targeted by the company include pain management, ophthalmology, and potentially new markets tied to diversified platform acquisitions. PRFX stock performance tends to be driven by clinical milestones, regulatory updates, and strategic deal announcements.

Clinical and regulatory developments

Clinical outcomes and regulatory milestones materially affect PRFX stock sentiment and valuation. For development‑stage companies such as PainReform, the following types of events are commonly material:

• Early‑stage trial results: Results from Phase 1, Phase 2 or Phase 3 clinical trials for candidates like PRF‑110 influence investor interest. Positive safety and efficacy readouts can increase speculative demand for PRFX stock; negative readouts may trigger sharp sell‑offs.

• Regulatory interactions: Communications with regulators (for example, IND submissions, clinical trial authorizations, or feedback on endpoints) are key inflection points published in company filings or press releases. As of 2026-01-27, market pages and corporate releases referenced in Nasdaq and MarketWatch summaries list prior clinical updates and regulatory notices tied to PRFX stock.

• Announced setbacks: Any announced trial failures, enrollment pauses, or regulatory holds are significant for PRFX stock and are typically disclosed via press release and SEC filings.

• Potential impact: For PRFX stock, material clinical progress can de‑risk aspects of product candidates and make the company more attractive for partnerships or licensing; conversely, clinical setbacks often increase financing needs and can lead to dilution or heightened volatility.

Note: As a neutral informational resource, this article does not provide investment advice. Readers should consult company 8‑K/press release/SEC filings for precise clinical timelines and results; those documents are the authoritative source for assessing how trial outcomes affect PRFX stock.

Mergers, acquisitions and strategic investments

PRFX stock has been responsive to the company’s announced M&A and investment activity. Publicly reported corporate transactions have included purchases, majority investments or pilot agreements that management presents as strategic diversification. Key themes and examples reported in public materials include:

• LayerBio (majority investment): The company disclosed a majority investment or acquisition interest in LayerBio, a biotech or biomaterials entity, to expand its IP base and access complementary technologies. Management framed this transaction as a way to extend product development capabilities beyond reformulation and into platform biology. Announcements tying LayerBio to PRFX stock activity appear in press releases and market summaries.

• DeepSolar (purchase or pilot): Public materials referenced an acquisition or pilot arrangement named DeepSolar, presented as an energy or solar‑related pilot project intended to diversify revenue streams. The stated rationale in disclosures is to pursue technology opportunities outside strict pharmaceutical reformulation.

• Rationale and synergies: Company statements accompanying these transactions typically emphasize cross‑platform synergies (for example, leveraging formulation expertise across therapeutics and materials science) and potential non‑dilutive revenue generation. Analysts and market watchers often note that diversifications of this type make PRFX stock more complex to value because it combines traditional biotech risk with technology/energy project risk.

• Integration and execution risk: Acquisitions and investments increase operational complexity; the market reaction to such deals is mixed and often depends on clarity of strategy and near‑term milestones. For PRFX stock holders, follow‑up filings and investor presentations are the primary source to assess realized synergies.

As of 2026-01-27, company press releases and market pages summarized by Nasdaq, CNBC and MarketWatch mention the transactions above as part of PainReform’s corporate strategy.

Stock listing and trading information

PRFX stock trades on the Nasdaq exchange under the ticker PRFX. The Nasdaq listing provides standard US market trading hours and access to US investor liquidity.

As of 2026-01-27, according to Nasdaq and MarketWatch data: PRFX stock is a small‑market‑capitalization security with typical trading characteristics of low absolute volume and higher percentage intraday volatility compared to larger pharmaceutical peers. These traits are common for development‑stage micro‑cap biotech companies.

• Exchange: Nasdaq (Ticker: PRFX)
• Typical trading hours: Regular Nasdaq market hours apply (09:30–16:00 Eastern Time), with pre‑market and after‑market sessions also possible through broker platforms. PRFX stock can therefore show moves outside regular hours on news releases.

As of 2026-01-27, Nasdaq and Barchart summaries list PRFX stock metrics such as market capitalization and float; readers should consult those primary pages for the real‑time quote and official market stats.

Historical price performance

PRFX stock has experienced the type of episodic volatility typical of small, development‑stage companies. Investors tracking PRFX stock commonly monitor these horizons:

• 1‑day moves: PRFX stock can show double‑digit percentage moves on single days when the company issues a clinical or corporate update.

• 1‑month moves: Over 30‑day windows, PRFX stock has exhibited both rapid rallies on positive news and sharp drawdowns on setbacks or dilution announcements.

• 1‑year and 52‑week range: PRFX stock’s 52‑week high and low are useful for understanding recent volatility; market pages such as MarketWatch, TradingView and Nasdaq publish the exact numeric high and low. As of 2026-01-27, those pages show a wide 52‑week trading range consistent with micro‑cap pharmaceutical peers.

• Extreme sessions and dilution events: PRFX stock has historically been sensitive to large‑volume sessions tied to news releases. Financing events (equity raises, convertible issuances or warrant exercises) reported in SEC filings can be sources of dilution that materially affect price per share.

Note: For precise historical percent changes, daily charts and volume footprints, refer to market data providers cited in the references section. This article emphasizes typical patterns rather than quoting intraday numeric ticks.

Market data and financial metrics

Market‑data providers list standard financial metrics for PRFX stock. Common fields and caveats include:

• Market capitalization: Market pages report market cap based on shares outstanding and latest price; for PRFX stock the market capitalization is in the small‑cap or micro‑cap range as of 2026‑01‑27, per Nasdaq and MarketWatch.

• Shares outstanding and float: The company’s SEC filings and market summaries list shares outstanding and the public float; for PRFX stock, these numbers are important because a small float can amplify volatility on news.

• Revenue and profitability metrics: As a development‑stage company with R&D focus, PainReform frequently reports limited or negative operating income and net income. Metrics such as EPS, P/E ratio and EBITDA can be negative or not meaningful; market pages typically flag negative valuations as “NM” (not meaningful) where applicable.

• Cash runway and balance sheet: Quarterly filings and investor presentations are the sources for cash on hand and burn rate, which are material for PRFX stock because future financing needs can lead to dilution.

• Trading volume: Daily average volume for PRFX stock is commonly lower compared with larger peers. Low liquidity is a known risk affecting bid/ask spreads and the ability to execute large orders without market impact.

Investors should treat some commonly reported metrics for PRFX stock with caution—particularly earnings multiples—because negative earnings and one‑time items distort standard ratios for early‑stage biotech firms.

Corporate governance and management

Corporate leadership and governance influence strategic direction for companies behind PRFX stock. Public materials and SEC disclosures list the company’s senior executives and board members; typical roles include Chairman, CEO, CFO and heads of R&D.

• Executive team: The CEO is the primary spokesperson for corporate strategy and clinical development timelines. Other senior executives typically include a CFO (managing financing and investor communications), a CTO or head of R&D (overseeing clinical programs), and senior managers for business development who drive M&A and partnering activity. PRFX stock announcements often quote the CEO and senior officers when describing trial results or acquisitions.

• Board composition: The board of directors commonly includes independent directors with industry experience and members representing significant investors or strategic partners. Material leadership changes—resignations, new CEO appointments or board member additions—are disclosed in 8‑K filings and press releases and can influence market perception of PRFX stock.

• Recent leadership changes: As of 2026-01-27, market pages such as CNBC and Nasdaq list current named executives for the company. Readers should consult the company’s latest SEC filings for official biographical details and dates of appointment for those roles.

Major shareholders and insider activity

Ownership patterns and insider transactions are important to understand when researching PRFX stock:

• Insider holdings: Company filings, such as Forms 3/4/5 and Section 16 reports, disclose beneficial ownership by executives and directors. Significant insider ownership can indicate alignment with long‑term shareholders, but the level of insider selling or buying is also closely watched by the market.

• Institutional ownership: PRFX stock typically shows lower institutional ownership compared with larger biopharma companies; public market pages (MarketWatch, Nasdaq) report the percentage held by institutions where available. As of 2026-01-27, institutional ownership for PRFX stock is reported as modest on major data providers.

• Recent insider transactions: Material insider purchases or sales are filed with the SEC and summarized on market pages. For PRFX stock, insiders’ activity around financing events or post‑announcement windows can be a source of market commentary.

• Ownership concentration: For micro‑cap companies, a small number of large shareholders or controlling stockholders can influence corporate decisions. PRFX stockholders should review 13D/G filings and the company’s proxy statements for details on ownership concentration and voting arrangements.

Investor relations and regulatory filings

Investors tracking PRFX stock should monitor the company’s official channels and mandated filings for authoritative information:

• SEC filings: Quarterly and annual reports, proxy statements and current reports (Forms 10‑Q, 20‑F where applicable for foreign private issuers, 8‑K) contain primary disclosure of financials, risk factors and corporate actions. The company’s filings are the authoritative source for PRFX stock‑related facts.

• Press releases and investor presentations: Management distributes operational updates, clinical results, and transaction announcements through press releases and investor decks; these are commonly summarized by market data providers.

• Investor relations contact: The company typically lists investor relations contact details on its corporate website and in filings for analysts and investors to request further information. PRFX stockholders can contact investor relations for clarifications or to request materials.

As of 2026-01-27, Nasdaq, MarketWatch and TradingView aggregate company news and link to the company’s filings and press release summaries for PRFX stock. Always reference the company’s filings when verifying material events.

News, analyst coverage and market sentiment

PRFX stock coverage in mainstream financial media and analyst reports is more limited than larger peers, but the stock is periodically discussed in specialized biotech news outlets and on retail investor platforms. Typical sentiment drivers include:

• Clinical updates and trial results — primary drivers of short‑term sentiment for PRFX stock.
• M&A or strategic investments — announcements about LayerBio, DeepSolar or other transactions tend to shift narrative from pure biotech to a hybrid technology/energy play, affecting comparability and investor interest.
• Financing and dilution — equity raises or convertible issuances often weigh on PRFX stock prices and investor sentiment.
• Social and retail interest — PRFX stock appears on some retail trading and discussion platforms where speculative interest can magnify intraday moves.

As of 2026-01-27, news pages on CNBC, MarketWatch and StockTwits provide episodic coverage and community commentary on PRFX stock. Analysts that do cover the company tend to be boutique biotech or small‑cap research shops; broad sell‑side coverage is uncommon for micro‑cap names.

Trading risks and controversies

Investors considering PRFX stock should be aware of common and material risks:

• Low liquidity and high volatility: PRFX stock’s typical low average volume can produce wide bid/ask spreads and rapid price swings on news.

• Trial risk: Clinical failure or regulatory setbacks for lead candidates such as PRF‑110 would be material and could substantially reduce the company’s market value.

• Dilution risk: Development‑stage companies frequently require external financing. Equity raises and conversions can dilute existing shareholders and pressure PRFX stock prices.

• Execution risk on diversification: Acquisitions or investments into non‑core areas (for example, energy pilots) create execution and integration risk. Markets may question the strategic fit and potential returns, affecting PRFX stock.

• Governance and transparency: Any concerns about timely disclosure, related‑party transactions, or management turnover are material for PRFX stock and are typically addressed in SEC filings and 8‑K disclosures.

• Regulatory or compliance events: Trading halts, SEC inquiries, or other regulatory actions would be material and reported via official exchange notices and SEC filings for PRFX stock.

As of 2026-01-27, major news sources and market pages have not consolidated a pervasive controversy beyond the standard set of small‑cap biotech risks; nonetheless, investors should review company filings for up‑to‑date risk disclosures.

Comparable companies and industry context

PRFX stock is best compared with other small‑cap pharmaceutical and biotech companies that focus on reformulation, early clinical trials or niche specialty programs. Comparable factors include:

• Development stage: Companies with preclinical to early clinical assets, similar cash burn profiles and reliance on licensing/partnerships.

• Market cap and liquidity: Micro‑cap biotechs with small public floats and episodic institutional interest.

• Diversification: A key distinguishing feature of the company behind PRFX stock is strategic diversification into technology/energy projects; this makes direct peer comparisons imperfect, because the company mixes biotech operational risk with technology/energy execution risk.

Analysts and investors often treat PRFX stock as a hybrid exposure and adjust comparables accordingly.

See also

• Nasdaq listing procedures and continuous disclosure
• Investing in clinical‑stage biotech: risk considerations
• Small‑cap and micro‑cap stock volatility and liquidity management

References and external links

As of 2026-01-27, the following primary market pages and news sources provide data and reporting for PRFX stock. Readers should consult these sources and the company’s SEC filings for authoritative figures and the latest updates:

• Nasdaq — PRFX market summary and company profile (Nasdaq market pages)
• MarketWatch — PRFX stock price and profile (MarketWatch PRFX page)
• TradingView — NASDAQ:PRFX chart and market data (TradingView PRFX page)
• CNBC — PRFX company headlines and profile (CNBC PRFX coverage)
• StockTwits — PRFX symbol discussion and sentiment aggregation (StockTwits PRFX page)
• Robinhood — PRFX overview page (Robinhood PRFX summary)
• Barchart / Public / Intellectia.ai — aggregated market data and analytics pages for PRFX stock
• Company press releases and SEC filings — primary source for corporate announcements, clinical results and transaction disclosures

(Reporting dates and data snapshots in this article reference material available and summarized on the listed pages as of 2026-01-27.)

Appendix / Infobox (suggested fields)

How to monitor PRFX stock and next steps

• Track live quotes and alerts on market data platforms (Nasdaq, MarketWatch, TradingView) for PRFX stock to receive real‑time price and volume updates.
• Review the company’s SEC filings and press releases for material clinical results, financing and transaction details that affect PRFX stock.
• For trading PRFX stock, consider using regulated broker platforms that support Nasdaq‑listed equities. For crypto or Web3 wallet references, Bitget Wallet is recommended where relevant for digital asset custody; for equity trading needs, Bitget’s trading platform provides market access and tools that may be useful for active traders.

As of 2026-01-27, analysts and media coverage for PRFX stock are episodic—clinical updates, M&A announcements and financing events remain the most common catalysts. For deeper analysis, combine primary filings, market data and independent research.

Further exploration: review the company’s most recent 8‑K/10‑Q (or 20‑F if applicable) and the Nasdaq company summary page for PRFX stock to confirm the latest figures and disclosures.

Editorial note on sources and dates

As of 2026-01-27, the descriptive and market commentary in this article is based on aggregated reporting and market data available on Nasdaq, MarketWatch, TradingView, CNBC, StockTwits, Robinhood, Barchart and company press releases. Readers should confirm current quotes and filings directly on the primary sources listed in the References section before making any decisions.

prfx stock prfx stock prfx stock prfx stock prfx stock prfx stock prfx stock prfx stock prfx stock prfx stock